Inclusive of all taxes
CID-0-RAB DSR Tablet by Dr Precision is a premium fixed-dose combination medication specifically formulated to effectively treat various acid-related gastrointestinal disorders. Containing 20 mg of Rabeprazole Sodium in an enteric-coated delayed-release form and 30 mg of sustained-release Domperidone, this tablet offers dual therapeutic benefits. Rabeprazole acts as a potent proton pump inhibitor to suppress gastric acid production by selectively inhibiting the H+/K+ ATPase enzyme on stomach parietal cells, ensuring relief from heartburn, acid reflux, and promoting ulcer healing. The enteric coating protects Rabeprazole from stomach degradation, enhancing its bioavailability and minimizing side effects. Domperidone, a dopamine D2 receptor antagonist, serves as a prokinetic agent promoting gastric motility and facilitates gastric emptying, which is crucial for patients experiencing bloating, nausea, and fullness due to delayed gastric emptying. This sustained-release Domperidone formulation delivers extended prokinetic and antiemetic effects lasting up to 24 hours, providing prolonged symptom control. Manufactured under rigorous WHO-GMP and ISO-certified conditions by BluepillExpress under the trusted Dr Precision label, this tablet ensures consistent quality and therapeutic efficacy. CID-0-RAB DSR Tablet is ideal for managing GERD, peptic ulcer disease, gastritis, functional and non-ulcer dyspepsia, and for the prevention of NSAID-induced ulcers, especially in patients requiring long-lasting symptom relief for acid reflux and associated gastrointestinal motility disorders.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Rabeprazole Sodium 20 mg (Enteric-coated), Domperidone 30 mg (Sustained-release) |
| Formulation Type | Dual delayed-release (Rabeprazole) and sustained-release (Domperidone) tablet |
| Primary Therapeutic Action | Proton pump inhibition and prokinetic effects |
| Indications | GERD, peptic ulcer, functional dyspepsia, acid reflux, gastritis, bloating, nausea |
| Manufacturing Standards | WHO-GMP, ISO-certified, GMP-compliant Dr Precision label |
| Duration of Action | Prolonged symptom control with up to 24-hour prokinetic effect |
| Protection Mechanism | Enteric coating protects Rabeprazole from stomach acid degradation |
| Market Availability | Available for both domestic and international B2B pharmaceutical distribution |
| Therapeutic Benefit | Effective acid suppression combined with improved gastric motility |
| Ideal Patient Profile | Patients with severe or chronic acid reflux and delayed gastric emptying |
| Attributes | Description |
|---|---|
| Dosage Strength | Rabeprazole 20 mg, Domperidone 30 mg |
| Dosage Form | Tablet |
| Release Mechanism | Rabeprazole - enteric-coated delayed release; Domperidone - sustained release |
| Drug Class | Proton pump inhibitor and gastrointestinal prokinetic agent |
| Packaging | Blister packs or bottles (customizable for B2B orders) |
| Shelf Life | Typically 24 months from manufacture date |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Manufacturer | BluepillExpress, Dr Precision label |
| Regulatory Compliance | WHO-GMP and ISO certified |
| Applications | Treatment of GERD, acid reflux, peptic ulcers, functional dyspepsia, and related GI disorders |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The enteric coating prevents Rabeprazole from being degraded by stomach acid, enabling it to reach the small intestine where it is absorbed and activated, resulting in more effective acid suppression and fewer gastrointestinal side effects.
The sustained-release form of Domperidone in CID-0-RAB DSR Tablet ensures prolonged gastrointestinal prokinetic action lasting up to 24 hours, improving gastric emptying and reducing symptoms such as bloating and nausea associated with delayed gastric motility.
Rabeprazole effectively reduces gastric acid secretion to heal ulcers and relieve heartburn, while Domperidone stimulates gastric motility to address delayed gastric emptying. This dual mechanism offers comprehensive symptom relief, especially for patients unresponsive to proton pump inhibitors alone.
Yes, this tablet is designed for prolonged symptom control with continuous acid suppression and improved gastric motility, making it appropriate for chronic or severe acid reflux conditions under medical supervision.
Yes, the Rabeprazole component reduces stomach acid secretion, lowering the risk of ulcer formation caused by NSAID use, thus providing a preventive benefit in patients requiring NSAIDs.
Country Of Origin: India
CID-0-RAB DSR Tablet is a combination medication containing Rabeprazole Sodium (20 mg) and Domperidone (30 mg) in a sustained-release/delayed-release formulation. It is used in the treatment of gastroesophageal reflux disease (GERD), chronic dyspepsia, acid reflux, and peptic ulcer disease. The dual-action formulation ensures prolonged suppression of gastric acid along with improved gastrointestinal motility, making it ideal for patients who require long-lasting symptom control. Manufactured under WHO-GMP and ISO-certified standards by BluepillExpress, this product offers consistent quality, patient comfort, and therapeutic efficacy for domestic and international markets.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
CID-0-RAB DSR Tablet is a fixed-dose combination of Rabeprazole Sodium 20 mg (enteric-coated) and Domperidone 30 mg (sustained-release) designed for the effective management of acid-related disorders of the upper gastrointestinal tract. It is commonly prescribed in the treatment of GERD (gastroesophageal reflux disease), peptic ulcer disease, non-ulcer dyspepsia, acid reflux, gastritis, post-meal bloating, and other functional GI disorders involving excess acid and delayed gastric emptying.
Rabeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the gastric H+/K+ ATPase enzyme located on the surface of parietal cells in the stomach. By blocking this enzyme, Rabeprazole significantly reduces the secretion of hydrochloric acid in the stomach, thereby lowering acidity, healing ulcers, and relieving symptoms such as heartburn, indigestion, and acid regurgitation. Being enteric-coated, Rabeprazole is protected from degradation in the stomach and becomes active only in the small intestine, ensuring maximum efficacy and minimum side effects.
Domperidone is a dopamine D2 receptor antagonist that acts as a gastrointestinal prokinetic agent. It facilitates the movement of food through the digestive tract by enhancing the motility of the stomach and intestines. Domperidone also has antiemetic properties by acting on the chemoreceptor trigger zone (CTZ) in the brain. In the sustained-release form used in CID-0-RAB DSR, Domperidone provides extended prokinetic action over 12 to 24 hours, promoting better gastric emptying and preventing symptoms like bloating, nausea, and a feeling of fullness.
The combination of these two agents in a dual-release formulation offers a comprehensive and long-acting approach to the treatment of functional gastrointestinal disorders. Rabeprazole takes care of the acid production, while Domperidone improves gastric motility and helps relieve discomfort associated with delayed gastric emptying. This makes CID-0-RAB DSR Tablet especially effective in managing patients with chronic or severe acid reflux symptoms that are not adequately controlled with standard PPIs alone.
This formulation is often recommended for:
Gastroesophageal reflux disease (GERD)
Peptic ulcers
Functional dyspepsia
Non-ulcer acid dyspepsia
Gastritis
Bloating and nausea related to delayed gastric emptying
Prevention of NSAID-induced ulcers
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
